secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268939
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio: ASH presentations show trem-cel engraftment; CD33CART 40% complete remission at highest dose
--------------------------------------------------------------------------------

- VBP101 (trem-cel) abstract accepted for oral at ASH; shows robust neutrophil engraftment and hematologic protection from Mylotarg.
- CD33CART Phase 1: 2/5 (40%) evaluable patients at DL4 achieved complete remission; 4/19 had CRS ≥ Grade 3.
- VCAR33 ALLO uses same CAR-T construct as CD33CART but from healthy donors; VBP301 trial-in-progress poster at ASH.
- Preclinical collaboration with Janssen: CD33-deleted allografts synergistic with JNJ-67571244, reducing cytokines.
- Single-cell analysis of 28 AML patients (most comprehensive to date) accepted for oral presentation at ASH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312523268939/0001193125-23-268939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312523268939/d554165d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer